靶向肺去神经术治疗中重度慢阻肺的安全性与不良事件:AIRFLOW多中心随机对照试验
结果显示,TLD组在随机化后3至6.5个月内的呼吸不良事件发生率显著低于假手术组(32% vs. 71%,P=0.008),且0至12.5个月内因COPD急性加重住院的风险显著降低(HR 0.35,95%CI 0.13-0.99,P=0.039)。
要点
- TLD可显著减少有症状中重度COPD患者的呼吸不良事件。
- TLD组因COPD急性加重住院的风险显著低于假手术组。
- TLD未改善首次中重度急性加重时间或患者报告症状。
核心结论
- 在接受最佳药物治疗的有症状COPD患者中,TLD可减少研究定义的呼吸不良事件,包括因COPD急性加重住院。
研究设计与样本
- 纳入标准为mMRC≥2或CAT≥10,且FEV1占预计值30-60%。
- 主要终点为随机化后3至6.5个月内的呼吸不良事件发生率,盲法维持至12.5个月。
主要发现
- TLD组在3至6.5个月窗口内的呼吸不良事件发生率为32%,假手术组为71%(P=0.008;OR 0.19;95%CI 0.0750-0.4923,P=0.0006)。
- 0至12.5个月期间,两组呼吸不良事件发生率无显著差异(83% vs. 90%;P=0.52)。
- 0至12.5个月内,TLD组因COPD急性加重住院的风险显著低于假手术组(HR 0.35;95%CI 0.13-0.99;P=0.039)。
- 两组在首次中重度COPD急性加重时间、患者报告症状或其他生理指标上无统计学差异。
关键数值与推荐
- 主要终点呼吸不良事件定义包括:COPD急性加重、呼吸急促、喘息、支气管炎加重、呼吸困难加重、流感、肺炎、其他呼吸道感染、呼吸衰竭或需治疗干预的气道效应。
临床怎么用
- 对于已接受最佳药物治疗仍有症状的中重度COPD患者,TLD可能作为减少呼吸不良事件和急性加重住院的辅助介入选项。
- 临床决策时需结合患者个体情况,并注意TLD对症状和肺功能等指标未见显著改善。
局限性
- 研究未显示TLD在患者报告症状或生理指标上的获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: Targeted lung denervation (TLD) is a bronchoscopic radiofrequency ablation therapy for chronic obstructive pulmonary disease (COPD), which durably disrupts parasympathetic pulmonary nerves to decrease airway resistance and mucus hypersecretion.Objectives: To determine the safety and impact of TLD on respiratory adverse events.Methods: We conducted a multicenter, randomized, sham bronchoscopy-controlled, double-blind trial in patients with symptomatic (modified Medical Research Council dyspnea scale score, ≥2; or COPD Assessment Test score, ≥10) COPD (FEV1, 30-60% predicted). The primary endpoint was the rate of respiratory adverse events between 3 and 6.5 months after randomization (defined as COPD exacerbation, tachypnea, wheezing, worsening bronchitis, worsening dyspnea, influenza, pneumonia, other respiratory infections, respiratory failure, or airway effects requiring therapeutic intervention). Blinding was maintained through 12.5 months.Measurements and Main Results: Eighty-two patients (50% female; mean ± SD: age, 63.7 ± 6.8 yr; FEV1, 41.6 ± 7.3% predicted; modified Medical Research Council dyspnea scale score, 2.2 ± 0.7; COPD Assessment Test score, 18.4 ± 6.1) were randomized 1:1. During the predefined 3- to 6.5-month window, patients in the TLD group experienced significantly fewer respiratory adverse events than those in the sham group (32% vs. 71%, P = 0.008; odds ratio, 0.19; 95% confidence interval, 0.0750-0.4923, P = 0.0006). Between 0 and 12.5 months, these findings were not different (83% vs. 90%; P = 0.52). The risk of COPD exacerbation requiring hospitalization in the 0- to 12.5-month window was significantly lower in the TLD group than in the sham group (hazard ratio, 0.35; 95% confidence interval, 0.13-0.99; P = 0.039). There was no statistical difference in the time to first moderate or severe COPD exacerbation, patient-reported symptoms, or other physiologic measures over the 12.5 months of follow-up.Conclusions: Patients with symptomatic COPD treated with TLD combined with optimal pharmacotherapy had fewer study-defined respiratory adverse events, including hospitalizations for COPD exacerbation.Clinical trial registered with www.clinicaltrials.gov (NCT02058459).
引用
- Slebos DJ, Shah PL, Herth FJF, et al. Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial. Am J Respir Crit Care Med. 2019. PMID: 31404499. doi:10.1164/rccm.201903-0624OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。